Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Dividends Paid

Cash distributed to shareholders as dividends.

Pulmonx CorporationNASDAQ: LUNG

Dividends Paid · Q1 FY2026 · quarter ended Mar 2026

Dividends paid outflow grows to $0

Q1 FY2026 dividends paid was $0, compared with $0 a year earlier. Trailing-twelve-month dividends paid was $0.

Context

  • Dividends paid amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Dividends paid increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly dividends paid holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Dividends Paid past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Dividends Paid history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Dividends Paid vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 dividends paid of $0 is the largest of the 10 companies compared; the peer median is $0.
  • Dividends paid amounts to 0.0% of revenue for LUNG, versus a peer median of 0.0%.
LUNG Competitors Peer median
Dividends Paid for LUNG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUNGPulmonx CorporationLTM Mar 2026$0 ——0.0%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
ASRTAssertio Holdings, Inc.LTM Mar 2026$0 ——0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 ———
VXRTVaxart, Inc.LTM Mar 2026$0 ——0.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
HYPRHyperfine, Inc.LTM Mar 2026$0 ——0.0%
TELATELA Bio, Inc.LTM Jun 2026$0 ——0.0%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding LUNG) $0——0.0%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Depreciation & Amortization3.16M4M1.55M1.49M1.15M
Deferred Income Tax(6K)49K000
Stock-Based Compensation0022.1M22.96M0
Change in Working Capital(7.84M)(7.06M)(2.56M)(1.7M)(1.93M)
Accounts Receivables(2.43M)(2.19M)(3.1M)(1.31M)1.08M
Inventory(6.46M)(3.64M)918K(229K)(765K)
Accounts Payables87K247K(345K)2.28M270K
Other Working Capital963K(1.48M)(27K)(2.44M)(2.51M)
Other Non-Cash Items11.92M16.8M2.14M2.11M22.33M
Operating Cash Flow(41.43M)(45.14M)(37.61M)(31.54M)(32.45M)
Capital Expenditures(3.67M)(1.32M)(807K)(1.45M)(452K)
Acquisitions (Net)00000
Purchases of Investments(52.58M)(47.19M)(46.2M)(27.91M)(5.65M)
Sales of Investments10M44.28M45M46.84M36.59M
Other Investing Activities00000
Investing Cash Flow(46.26M)(4.23M)(2.01M)17.48M30.48M
Debt Repayment0(87K)19.91M(95K)(100K)
Common Stock Issued4.52M2.59M001M
Common Stock Repurchased(26K)(27K)000
Dividends Paid00000
Other Financing Activities001.49M1.46M0
Financing Cash Flow4.5M2.47M21.4M1.36M903K
Effect of Forex Changes106K145K34K76K(92K)
Net Change in Cash(83.08M)(46.74M)(18.18M)(12.62M)(1.15M)
Free Cash Flow(45.1M)(46.45M)(38.42M)(32.98M)(32.9M)

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.